Bristol Myers Squibb & Co (NYSE:BMY) announced on Saturday (June 1) results from the Phase 3 KRYSTAL-12 study evaluating Krazati (adagrasib) compared to standard-of-care chemotherapy for locally advanced or metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) which previously received platinum-based chemotherapy, concurrently or sequentially with anti-PD-(L)1 therapy. At a median follow-up of 9.4 months, Krazati demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), the study’s primary endpoint, compared to docetaxel. Median PFS was 5.5 months for Krazati compared to 3.8 months for docetaxel. The overall response rate was also significantly higher with Krazati compared to docetaxel (32% vs. 9%). The median duration of response (mDOR) was 8.31 months versus 5.36 months (95% CI, 2.86–8.54), respectively. Krazati demonstrated intracranial response among patients with central nervous system (CNS) metastases at ...